794P Efficacy and tolerability of neoadjuvant treatment with T-VEC in difficult to resect primary basal cell carcinoma: A phase II clinical trial (NeoBCC)

• DOI: 10.1016/j.annonc.2022.07.920
• Publication Date: 2022-09-13T18:51:30Z
• Authors: J.M. Ressler; A. Kusienicka; R. Silmbrod; T. Silly; V. Bachmayr; M. Plaschka; L.E. Shaw; N. Zila; A. Stepan; P. Tschandl; J. Tittes; F. Roka; W. Haslik; F. Koenig; R. Kunstfeld; P. Petzelbauer; F. Halbritter; W. Weninger; M. Farlik; C. Hoeller
• Keywords: Clinical endpoint; Tolerability